Semax's calmer sibling
1990-1995 (approx.)
Selank's chief ingredient, tuftsin, wasn't named for anything Russian at all — it's named after Tufts University in Boston, where it was discovered in 1970.
In the early 1980s, at Moscow's Institute of Molecular Genetics (IMG), academicians Ivan Ashmarin and Nikolai Myasoedov had a maddening problem. A fragment of ACTH — the pituitary stress hormone — sharpened animals' minds, but like nearly every short peptide, blood enzymes shredded it within minutes. Their fix was almost carpentry: staple a tiny Pro-Gly-Pro (proline-glycine-proline) tail onto the molecule's end to shield it from those enzymes. The stabilized result became Semax, approved in Russia for stroke recovery.
That Pro-Gly-Pro 'patch' worked so well as an engineering trick that, a decade later, the same institute (with the V.V. Zakusov Institute of Pharmacology) bolted the identical stabilizer onto a completely different starting molecule — tuftsin, an immune-signaling tetrapeptide that was discovered and classically characterized as a peripheral spleen peptide, with no connection to the ACTH/neurotrophic pathway that had produced Semax. The result was Selank, created at IMG sometime in the 1990s — though sources disagree on the exact year, ranging from a 1989 patent reference to 'late 1990s,' with no independently verified primary date. So Selank is Semax's 'calmer sibling' not by biological descent, but because both were built with the same repair patch grafted onto different donor molecules.
Here's the genuinely surprising bit, sitting one layer deeper. Tuftsin — the Thr-Lys-Pro-Arg fragment that donates Selank its first four amino acids — wasn't Russian at all. It was isolated in 1970 by Victor Najjar and Keisuke Nishioka at Tufts University School of Medicine in Boston, published in Nature, and named for the very university where it was found. A molecule now marketed as a quintessentially 'Russian' nootropic has an American university's name baked right into its chemistry.
The strongest evidence for Selank's calming reputation comes from a 2008 head-to-head trial (Zozulya and colleagues) that pitted it against medazepam, a benzodiazepine, in 62 patients with anxiety and neurasthenia over two weeks. Both groups' anxiety eased by roughly the same amount — but the Selank patients also reported less fatigue and a faint stimulant-like lift the benzodiazepine group never got. That single result is the seed of the whole 'anxiolytic without the sedation' pitch that follows Selank around to this day.
The bones of this story hold up — the Tufts naming, the Semax-then-Selank engineering reuse, the IMG scientists behind it, and the 2008 medazepam trial all check out against independent sources. It earns an "embellished" tag only because the tidy timeline glosses over real uncertainty: Selank's exact creation year is genuinely disputed (anywhere from 1989 to the late 1990s), and tuftsin isn't quite as brain-irrelevant as a clean origin tale implies.
Selank is approved and prescribed in Russia as <b>Selanc</b>, a 0.15% intranasal spray, for generalized anxiety disorder and neurasthenia — a status it has held since the 2000s. Everywhere else, including the US and EU, it is an unapproved, unscheduled research-use peptide sold online with no legal compounding pathway: a 2024 attempt to add it to the FDA's compounding-pharmacy nomination list was withdrawn, and a rumored 2026 reclassification had not been formally enacted as of this writing. It keeps a small but stubborn following in the nootropic and biohacker scene, riding mostly on that one Russian clinical trial rather than Western-regulator-grade proof.
